The Effect of PEGylated Graphene Oxide Nanoparticles on the Th17-Polarization of Activated T Helpers.
IL-17-producing helper T cells (Th17)
PEGylated graphene oxide
cytokine profile
naïve T helper polarization
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
16 Jan 2023
16 Jan 2023
Historique:
received:
07
12
2022
revised:
06
01
2023
accepted:
12
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
We investigated the direct effect of PEGylated graphene oxide (P-GO) nanoparticles on the differentiation, viability, and cytokine profile of activated T helper type 17 (Th17) in vitro. The subject of the study were cultures of "naive" T-helpers (CD4+) isolated by immunomagnetic separation and polarized into the Th17 phenotype with a TCR activator and cytokines. It was found that P-GO at low concentrations (5 µg/mL) had no effect on the parameters studied. The presence of high concentrations of P-GO in T-helper cultures (25 μg/mL) did not affect the number and viability of these cells. However, the percentage of proliferating T-helpers in these cultures was reduced. GO nanoparticles modified with linear polyethylene glycol (PEG) significantly increased the percentage of Th17/22 cells in cultures of Th17-polarized T helpers and the production of IFN-γ, whereas those modified with branched PEG suppressed the synthesis of IL-17. Thus, a low concentration of PEGylated GO nanoparticles (5 μg/mL), in contrast to a concentration of 25 μg/mL, has no effect on the Th17-polarization of T helpers, allowing their further use for in-depth studies of the functions of T lymphocytes and other immune cells. Overall, we have studied for the first time the direct effect of P-GO nanoparticles on the conversion of T helper cells to the Th17 phenotype.
Identifiants
pubmed: 36676614
pii: ma16020877
doi: 10.3390/ma16020877
pmc: PMC9865146
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Russian Science Foundation
ID : 19-15-00244-П
Références
Immunology. 2021 May;163(1):3-18
pubmed: 33064842
J Transl Med. 2014 May 21;12:138
pubmed: 24885781
Int J Nanomedicine. 2017 Sep 07;12:6633-6646
pubmed: 28924347
Nanoscale. 2021 Jun 28;13(24):10748-10764
pubmed: 34132312
Front Immunol. 2021 Jul 06;12:688066
pubmed: 34295334
Biomaterials. 2017 Nov;146:13-28
pubmed: 28892752
J Exp Med. 2007 Nov 26;204(12):2803-12
pubmed: 18025126
Cytokine. 2015 Jul;74(1):43-53
pubmed: 25828206
Cell Immunol. 2011;271(1):78-84
pubmed: 21802072
AIDS. 2015 Jun 19;29(10):1263-5
pubmed: 26035325
Nat Immunol. 2007 Jun;8(6):639-46
pubmed: 17486092
Biomaterials. 2012 Sep;33(27):6559-69
pubmed: 22704844
Scand J Immunol. 2021 May;93(5):e13030
pubmed: 33576072
Biomaterials. 2011 Aug;32(22):5206-12
pubmed: 21492934
Int J Mol Sci. 2020 Feb 29;21(5):
pubmed: 32121394
Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):195-215
pubmed: 26502273
Cytometry A. 2011 Aug;79(8):646-52
pubmed: 21695774
Curr Opin Immunol. 2007 Feb;19(1):39-45
pubmed: 17129718
Mutat Res Genet Toxicol Environ Mutagen. 2022 Jun;878:503483
pubmed: 35649677
Front Oncol. 2019 Oct 04;9:1002
pubmed: 31637216
J Am Soc Nephrol. 2010 Jun;21(6):974-85
pubmed: 20299360
BMC Complement Altern Med. 2019 Mar 4;19(1):54
pubmed: 30832648
Bull Exp Biol Med. 2022 Mar;172(5):664-670
pubmed: 35353288
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
BMC Immunol. 2020 Oct 30;21(1):56
pubmed: 33126863
Adv Healthc Mater. 2016 Jan 21;5(2):276-87
pubmed: 26687729
Nat Commun. 2017 Oct 24;8(1):1109
pubmed: 29061960
Adv Healthc Mater. 2014 Sep;3(9):1486-95
pubmed: 24652749
Mod Rheumatol. 2018 Sep;28(5):814-825
pubmed: 29251019
J Allergy Clin Immunol. 2012 Jun;129(6):1438-49; quiz1450-1
pubmed: 22657405
J Biomed Mater Res A. 2017 Mar;105(3):728-736
pubmed: 27770563
Int J Mol Sci. 2022 Sep 13;23(18):
pubmed: 36142540
Nat Immunol. 2004 Oct;5(10):987-95
pubmed: 15454922
BMC Res Notes. 2022 Feb 10;15(1):42
pubmed: 35144659
Nanoscale. 2015 Oct 7;7(37):15214-24
pubmed: 26315610
Immunity. 2010 May 28;32(5):692-702
pubmed: 20434372
Int J Nanomedicine. 2018 May 17;13:2907-2919
pubmed: 29844673
Nanomaterials (Basel). 2021 Dec 30;12(1):
pubmed: 35010076
In Vitro Cell Dev Biol Anim. 2011 Sep;47(8):581-92
pubmed: 21853398
Microbiol Immunol. 2017 Feb;61(2):49-56
pubmed: 28225165
J Clin Med. 2017 Jul 10;6(7):
pubmed: 28698517
Front Immunol. 2017 Mar 31;8:254
pubmed: 28408906
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):16968-73
pubmed: 21969544
Sci Rep. 2020 Oct 27;10(1):18407
pubmed: 33110217
Clin Exp Immunol. 2005 Jun;140(3):395-407
pubmed: 15932500
Immunol Rev. 2008 Jun;223:87-113
pubmed: 18613831
Sci Rep. 2017 Oct 11;7(1):12962
pubmed: 29021537
Arthritis Res Ther. 2015 Nov 30;17:344
pubmed: 26617177
Brain. 2018 May 1;141(5):1334-1349
pubmed: 29659729
Int J Med Sci. 2021 Jan 1;18(1):99-108
pubmed: 33390778
Am J Respir Crit Care Med. 2011 Jan 15;183(2):204-14
pubmed: 20709824
J Control Release. 2016 Mar 28;226:217-28
pubmed: 26873333
J Clin Invest. 2009 Dec;119(12):3573-85
pubmed: 19920355